Free Trial

LianBio (LIAN) Competitors

LianBio logo
$0.05 0.00 (-1.82%)
As of 07/21/2025

LIAN vs. DRUG, GALT, IMAB, TLSA, DERM, CYBN, DMAC, NVCT, PBYI, and ACRS

Should you be buying LianBio stock or one of its competitors? The main competitors of LianBio include Bright Minds Biosciences (DRUG), Galectin Therapeutics (GALT), I-Mab (IMAB), Tiziana Life Sciences (TLSA), Journey Medical (DERM), Cybin (CYBN), DiaMedica Therapeutics (DMAC), Nuvectis Pharma (NVCT), Puma Biotechnology (PBYI), and Aclaris Therapeutics (ACRS). These companies are all part of the "pharmaceutical products" industry.

LianBio vs. Its Competitors

Bright Minds Biosciences (NASDAQ:DRUG) and LianBio (NASDAQ:LIAN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bright Minds BiosciencesN/AN/A-$2.06M-$0.36-83.00
LianBioN/AN/A-$110.29M-$0.81-0.07

40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 74.8% of LianBio shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by company insiders. Comparatively, 7.6% of LianBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Bright Minds Biosciences' return on equity of -14.56% beat LianBio's return on equity.

Company Net Margins Return on Equity Return on Assets
Bright Minds BiosciencesN/A -14.56% -14.29%
LianBio N/A -33.17%-30.19%

In the previous week, Bright Minds Biosciences had 2 more articles in the media than LianBio. MarketBeat recorded 2 mentions for Bright Minds Biosciences and 0 mentions for LianBio. Bright Minds Biosciences' average media sentiment score of 0.81 beat LianBio's score of 0.00 indicating that Bright Minds Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Bright Minds Biosciences Positive
LianBio Neutral

Bright Minds Biosciences has a beta of -6.01, suggesting that its stock price is 701% less volatile than the S&P 500. Comparatively, LianBio has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500.

Bright Minds Biosciences presently has a consensus target price of $83.25, indicating a potential upside of 178.61%. Given Bright Minds Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Bright Minds Biosciences is more favorable than LianBio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bright Minds Biosciences
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.13
LianBio
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Bright Minds Biosciences beats LianBio on 11 of the 14 factors compared between the two stocks.

Get LianBio News Delivered to You Automatically

Sign up to receive the latest news and ratings for LIAN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LIAN vs. The Competition

MetricLianBioBiotechnology IndustryMedical SectorNASDAQ Exchange
Market Cap$5.84M$135.38M$5.57B$9.42B
Dividend YieldN/A3.74%4.05%3.99%
P/E Ratio-0.073.7228.0920.08
Price / SalesN/A4,296.05403.9184.07
Price / CashN/A13.1936.1958.45
Price / Book0.0242.308.615.83
Net Income-$110.29M-$90.99M$3.24B$258.27M
7 Day PerformanceN/A3.67%3.53%2.69%
1 Month PerformanceN/A7.77%10.99%12.91%
1 Year PerformanceN/A189.36%35.43%21.81%

LianBio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LIAN
LianBio
N/A$0.05
-1.8%
N/A-82.6%$5.84MN/A-0.07110
DRUG
Bright Minds Biosciences
2.4673 of 5 stars
$24.36
-5.0%
$83.25
+241.7%
+2,591.9%$180.68MN/A-67.66N/ANews Coverage
GALT
Galectin Therapeutics
2.4958 of 5 stars
$2.80
-1.8%
$6.00
+114.3%
+8.9%$180.38MN/A-3.899Gap Up
IMAB
I-Mab
2.8992 of 5 stars
$2.10
-1.9%
$6.00
+185.7%
+47.6%$174.75M$3.89M0.00380
TLSA
Tiziana Life Sciences
1.2296 of 5 stars
$1.47
-0.7%
N/A+97.8%$172.93MN/A0.008
DERM
Journey Medical
1.6318 of 5 stars
$6.98
-5.8%
$9.50
+36.1%
+36.6%$172.62M$56.13M-17.9090Positive News
CYBN
Cybin
2.7164 of 5 stars
$7.46
-0.1%
$85.00
+1,039.4%
N/A$171.99MN/A-1.7050
DMAC
DiaMedica Therapeutics
1.2132 of 5 stars
$4.30
+7.2%
$8.00
+86.0%
+49.7%$171.96MN/A-6.7220Positive News
High Trading Volume
NVCT
Nuvectis Pharma
2.3157 of 5 stars
$8.28
+0.7%
$17.00
+105.3%
+17.0%$171.74MN/A-7.338
PBYI
Puma Biotechnology
4.2483 of 5 stars
$3.46
+0.3%
$7.00
+102.3%
-7.0%$171.23M$230.50M4.49200Upcoming Earnings
ACRS
Aclaris Therapeutics
1.6905 of 5 stars
$1.52
-3.8%
$8.71
+473.3%
+20.0%$171.08M$17.78M-1.09100

Related Companies and Tools


This page (NASDAQ:LIAN) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners